Connect with us


Study to explore effects of CBD on the heart



The study will examine the effects of CBD on targeted cardiology markers

A new study will investigate the potential effects of CBD on heart function for the first time. 

Researchers at Mount Sinai Medical Hospital in New York will examine the effects that CBD may have on cardiology markers in a six-month clinical trial which may prove “groundbreaking” for the field.

The clinical trial consists of two studies conducted by Dr David Harnick, a prominent cardiologist and assistant professor of medicine and cardiology at Mount Sinai Medical Hospital.

It has been constructed to gather data that will help in the deeper understanding of the effects CBD has on the body.

US health and wellness CBD company, HempFusion has announced that its products had been chosen as the exclusive provider by Dr Harnick, who commented: “Studying the potential effects that CBD may have on cardiology markers may potentially unlock some of the scientific mysteries that exist today. 

“We know that there is evidence that CBD may have beneficial effects on the body, but the exact scope of those effects remains to be determined. There have been no published randomised prospective controlled trials evaluating the effects of CBD on these cardiac markers, so this research may prove to be groundbreaking.” 

The study is expected to commence in March 2021 and it will be one-of-a-kind in the area of the effects of CBD on targeted cardiology markers.

Dr. Harnick chose HempFusion for its rigorous regulatory standards, toxicology studies for safety, and adherence to quality control.

The company also recently partnered with ValidCare as a co-sponsor alongside 12 other companies in the CBD space, collaborated in an industry-wide Human Observational liver and male reproductive toxicology studies, which explore the effects that full-spectrum hemp-derived CBD has on the liver.

“This is the second clinical trial HempFusion is proudly participating in,” HempFusion Wellness CEO Jason Mitchel, N.D. said.

“We are committed to furthering research in the area of hemp-derived CBD and this study [with Dr. Harnick] is a significant expansion of our efforts that reinforces our continued focus on the safe and effective use of hemp-derived CBD products,” he added. 

The CBD used in these trials is the same product the company offers to the public.

Sarah Sinclair is a respected cannabis journalist writing on subjects related to science, medicine, research, health and wellness. She is managing editor of Cannabis Health, the UK’s leading title covering medical cannabis and CBD, and sister titles, Cannabis Wealth and Psychedelic Health. Sarah has an NCTJ journalism qualification and an MA in Journalism from the University of Sunderland. Sarah has over six years experience working on newspapers, magazines and digital-first titles, the last two of which have been in the cannabis sector. She has also completed training through the Medical Cannabis Clinicians Society securing a certificate in Medical Cannabis Explained. She is a member of PLEA’s (Patient-Led Engagement for Access) advisory board, has hosted several webinars on cannabis and women's health and has moderated at industry events such as Cannabis Europa. Sarah Sinclair is the editor of Cannabis Health. Got a story? Email / Follow us on Twitter: @CannabisHNews / Instagram: @cannabishealthmag


Cannabis Health is a journalist-led news site. Any views expressed by interviewees or commentators do not reflect our own. All content on this site is intended for educational purposes, please seek professional medical advice if you are concerned about any of the issues raised.

Copyright © 2023 PP Intelligence Ltd.